ITF Therapeutics is the US affiliate of Italfarmaco Group. ITF Therapeutics launched DUVYZAT (givinostat), for the treatment of Duchenne muscular dystrophy (DMD), in July 2024, and has achieved broad adoption.

ITF is seeking to advance the organization’s rare disease strategy through partnerships on late-stage or marketed rare disease assets/programs. The company has leadership, development experience and structures in place to rapidly advance development programs to approval and commercial launch.

Conference Focus:

•In-licensing or of late stage (Ph 2/3) assets in rare or ultra rare diseases with significant unmet need, especially neuromuscular, neurodegenerative diseases, pediatric neurology, congenital myopathies, muscular dystrophies, lysosomal storage disorders or metabolic, or genetic disorders with CNS or muscle involvement.

•M&A or in-licensing of marketed assets in rare or ultra-rare diseases especially in neuromuscular, neurodegenerative disease or pediatric neurology